- Molecular NameBosentan
- Synonymbosentan; Bosentan hydrate
- Weight551.624
- Drugbank_IDDB00559
- ACS_NO147536-97-8
- Show 3D model
- LogP (experiment)4.625
- LogP (predicted, AB/LogP v2.0)3.92
- pkaN/A
- LogD (pH=7, predicted)1.87
- Solubility (experiment)0.01 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-2.12
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.2
- No.of HBond Donors2
- No.of HBond Acceptors11
- No.of Rotatable Bonds11
- TPSA154.03
- StatusFDA approved
- AdministrationN/A
- PharmacologyA dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH).
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability50.0
- Protein binding98.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmBosentan is metabolized in the liver by the cytochrome P450 enzymes CYP2C9 and CYP3A4 (and possibly CYP2C19), producing three metabolites, one of which, Ro 48-5033, is pharmacologically active and may contribute 10 to 20% to the total activity of the parent compound.
- Half life5 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityBosentan has been given as a single dose of up to 2400 mg in normal volunteers, or up to 2000 mg/day for 2 months in patients, without any major clinical consequences. The most common side effect was headache of mild to moderate intensity. In the cyclosporine A interaction study, in which doses of 500 and 1000 mg b.i.d. of bosentan were given concomitantly with cyclosporine A, trough plasma concentrations of bosentan increased 30-fold, resulting in severe headache, nausea, and vomiting, but no serious adverse events. Mild decreases in blood pressure and increases in heart rate were observed. There is no specific experience of overdosage with bosentan beyond the doses described above. Massive overdosage may result in pronounced hypotension requiring active cardiovascular support.
- LD50 (rat)N/A
- LD50 (mouse)N/A